IBSA UK&I has confirmed that it will assume direct oversight of the commercialisation and distribution of ialuril® throughout the United Kingdom and Ireland, effective from 9 April 2026.
Ensuring a stable supply chain and a smooth handover for customers is the company’s immediate focus. Oxford Pharmacy Store (OPS) has been appointed as the principal NHS distribution partner, responsible for processing orders and supplying NHS organisations, with direct support from IBSA UK&I. The product will also remain available via AAH Pharmaceuticals and Alliance as alternative supply channels.
Developed and manufactured by IBSA, ialuril® forms part of the company’s broader expertise in hyaluronic acid-based therapies. IBSA is internationally regarded for its leadership in this field and continues to invest in advancing treatments within urology and uro-gynaecology. Taking direct control of commercial activities reflects a strategic step in strengthening stewardship of the product.
The transition follows the launch of IBSA’s UK affiliate in 2022, which enabled the organisation to oversee its commercial strategy locally. Bringing ialuril® under direct management ensures alignment with IBSA UK&I’s expanding portfolio in uro-gynaecology, including Hyaluxelle® and Perovial®.
ialuril® (sodium hyaluronate, sodium chondroitin sulphate and calcium chloride) is presented as a 50ml pre-filled syringe equipped with a Luer-Lock Adapter and ialuadapter®, with no changes to its composition, format, or clinical purpose. It continues to be used to restore the glycosaminoglycan (GAG) layer of the bladder lining, particularly in patients experiencing recurrent issues such as cystitis from various causes.
Aspire Pharma has represented IBSA in the UK and Ireland for more than a decade, helping to ensure consistent access to ialuril® for healthcare providers. IBSA has acknowledged and thanked Aspire Pharma for its longstanding partnership and support.
Steven Knapp, General Manager of IBSA UK&I, said: “We are pleased to take on direct responsibility for ialuril® in the UK and Ireland. This transition reflects IBSA’s growing commitment to the urology and uro-gynaecology therapy area and allows us to work more closely with healthcare professionals and NHS partners. Our focus is on ensuring continuity of supply and strengthening the support we provide to clinicians so that patients can continue to access effective treatment.”
